Genetics of common endocrine disease: The present and the future

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 3, 2016, Pages 787-794

  Goodarzi, Mark O ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SEX HORMONE BINDING GLOBULIN;

ARTICLE; BIOINFORMATICS; CHROMATIN IMMUNOPRECIPITATION; CHROMATIN STRUCTURE; COHORT ANALYSIS; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG TARGETING; ENDOCRINE DISEASE; FTO GENE; GENE; GENE EXPRESSION; GENE FUNCTION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOMICS; GENOTYPE ENVIRONMENT INTERACTION; GLP1R GENE; HERITABILITY; HUMAN; HYPERANDROGENISM; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; IRX3 GENE; IRX5 GENE; KCNJ11 GENE; LATENT AUTOIMMUNE DIABETES OF ADULT; LOSS OF FUNCTION MUTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OVARY POLYCYSTIC DISEASE; PCSK9 GENE; PPARG GENE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; CLASSIFICATION; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY;

ENDOCRINE SYSTEM DISEASES; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84960910157     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-3640     Document Type: Article

References (52)

1. Welter D, Mac Arthur J, Morales J, et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res. 2014;42:D1001-D1006.
2. Lango H, Palmer CN, Morris AD, et al. Assessing the combined impact of 18 common genetic variants of modest effect sizes on type 2 diabetes risk. Diabetes. 2008;57:3129-3135.
3. Meigs JB, Shrader P, Sullivan LM, et al. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med. 2008;359:2208-2219.
4. van Hoek M, Dehghan A, Witteman JC, et al. Predicting type 2 diabetes based on polymorphisms from genome-wide association studies: a population-based study. Diabetes. 2008;57:3122-3128.
5. Talmud PJ, Cooper JA, Morris RW, et al. Sixty-five common genetic variants and prediction of type 2 diabetes. Diabetes. 2015;64:1830-1840.
6. Sturm AC, Kline CF, Glynn P, et al. Use of whole exome sequencing for the identification of Ito-based arrhythmia mechanism and therapy. J Am Heart Assoc. 2015;4:pii:e001762.
7. Mohlke KL, Boehnke M. Recent advances in understanding the genetic architecture of type 2 diabetes. Hum Mol Genet. 2015;24: R85-R92.
8. Wessel J, Chu AY, Willems SM, et al. Low-frequencyandrareexome chip variants associate with fasting glucose and type 2 diabetes susceptibility. Nat Commun. 2015;6:5897.
9. Segrè AV, Wei N, DIAGRAM Consortium, MAGIC Investigators, Altshuler D, Florez JC. Pathways targeted by antidiabetes drugs are enriched for multiple genes associated with type 2 diabetes risk. Diabetes. 2015;64:1470-1483.
10. Scuteri A, Sanna S, Chen WM, et al. Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. PLoS Genet. 2007;3:e115.
11. Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007;316:889-894.
12. Claussnitzer M, Dankel SN, Kim KH, et al. FTO obesity variant circuitry and adipocyte browning in humans. N Engl J Med. 2015; 373:895-907.
13. Smemo S, Tena JJ, Kim KH, et al. Obesity-associated variants within FTO form long-range functional connections with IRX3. Nature. 2014;507:371-375.
14. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264-1272.
15. Navarese EP, Kolodziejczak M, Schulze V, et al. Effects of propro-tein convertase subtilisin/kexin type 9 antibodies in adults with hy-percholesterolemia: a systematic review and meta-analysis. Ann Intern Med. 2015;163:40-51.
16. Tung YC, Yeo GS, O'Rahilly S, Coll AP. Obesityand FTO:changing focus at a complex locus. Cell Metab. 2014;20:710-718.
17. Rosse SA, Auer PL, Carlson CS. Functional annotation of putative regulatory elements at cancer susceptibility loci. Cancer Inform. 2014;13:5-17.
18. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489:57-74.
19. Chadwick LH. The NIH Roadmap Epigenomics Program data resource. Epigenomics. 2012;4:317-324.
20. Chen CY, Chang IS, Hsiung CA, Wasserman WW. On the identification of potential regulatory variants within genome wide association candidate SNP sets. BMC Med Genomics. 2014;7:34.
21. Lo KS, Vadlamudi S, Fogarty MP, Mohlke KL, Lettre G. Strategies to fine-map genetic associations with lipid levels by combining epig-enomic annotations and liver-specific transcription profiles. Genomics. 2014;104:105-112.
22. Hazelett DJ, Rhie SK, Gaddis M, et al. Comprehensive functional annotation of 77 prostate cancer risk loci. PLoS Genet. 2014;10: e1004102.
23. Yao L, Tak YG, Berman BP, Farnham PJ. Functional annotation of colon cancer risk SNPs. Nat Commun. 2014;5:5114.
24. Lowe WL Jr, Reddy TE. Genomic approaches for understanding the genetics of complex disease. Genome Res. 2015;25:1432-1441.
25. Himsworth HP. Diabetes mellitus: its differentiation into insulin-sensitive and insulin-insensitive types. Lancet. 1936;227:127-130.
26. Umpierrez GE, Smiley D, Kitabchi AE. Narrative review: ketosis-prone type 2 diabetes mellitus. Ann Intern Med. 2006;144:350-357.
27. Pearson ER, Flechtner I, Njølstad PR, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med. 2006;355:467-477.
28. Raile K, Schober E, Konrad K, et al. Treatment of young patients with HNF1A mutations (HNF1A-MODY). Diabet Med. 2015;32:526-530.
29. Oram RA, Hill A, McDonald TJ, et al. A novel, inexpensive test can discriminate between type 1 and type 2 diabetes. Diabetes. 2015; 64(suppl 1):A453 (Abstract 1745-P).
30. Patel KA, Weedon MN, Ellard S, Oram RA, Hattersley AT. Type 1 diabetes genetic risk score-a novel tool to differentiate monogenic diabetes from T1D. Diabetes. 2015;64 (suppl 1):A453 (Abstract 1746-P).
31. Kavvoura FK, Moutsianas L, Bennett AJ, et al. Can genomic information aid in establishing aetiology of young adult onset diabetes? Diabetes. 2015;64(suppl 1):A452 (Abstract 1744-P).
32. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81: 19-25.
33. Nestler JE, Powers LP, Matt DW, et al. A direct effect of hyperin-sulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 1991;72:83-89.
34. Chen ZJ, Zhao H, He L, et al. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat Genet. 2011;43:55-59.
35. Hayes MG, Urbanek M, Ehrmann DA, et al. Genome-wide association of polycystic ovary syndrome implicates alterations in gonad-otropin secretion in European ancestry populations. Nat Commun. 2015;6:7502.
36. Shi Y, Zhao H, Shi Y, et al. Genome-wideassociationstudy identifies eight new risk loci for polycystic ovary syndrome. Nat Genet. 2012; 44:1020-1025.
37. Day FR, Hinds DA, Tung JY, et al. Causal mechanisms and balancing selection inferred from genetic associations with polycystic ovary syndrome. Nat Commun. 2015;6:8464.
38. Shim U, Kim HN, Lee H, OH JY, Sung YA, Kim HL. Pathway analysis based on a genome-wide association study of polycystic ovary syndrome. PLoS One. 2015;10:e0136609.
39. Srouji SS, Pagán YL, D'Amato F, et al. Pharmacokinetic factors contribute to the inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome. J Clin Endo-crinol Metab. 2007;92:1347-1352.
40. Pagán YL, Srouji SS, Jimenez Y, Emerson A, Gill S, Hall JE. Inverse relationshipbetween luteinizinghormone andbody mass index inpoly-cystic ovarian syndrome: investigation of hypothalamic and pituitary contributions. J Clin Endocrinol Metab. 2006;91:1309-1316.
41. Jones MR, Brower MA, Xu N, et al. Systems genetics reveals the functional contextofPCOS loci and identifies genetic and molecular mechanisms of disease heterogeneity. PLoS Genet. 2015;11: e1005455.
42. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing herita-bility of complex diseases. Nature. 2009;461:747-753.
43. Clark MJ, Chen R, Lam HY, et al. Performance comparison of exome DNA sequencing technologies. Nat Biotechnol. 2011;29:908-914.
44. Lam HY, Clark MJ, Chen R, et al. Performance comparison of whole-genome sequencing platforms. Nat Biotechnol. 2012;30:78-82.
45. Multhaup ML, Seldin MM, Jaffe AE, et al. Mouse-human experimental epigenetic analysis unmasks dietary targets and genetic liability for diabetic phenotypes. Cell Metab. 2015;21:138-149.
46. Chen R, Mias GI, Li-Pook-Than J, et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell. 2012;148: 1293-1307.
47. Pasquali L, Gaulton KJ, Rodríguez-Seguí SA, et al. Pancreatic islet enhancer clusters enriched in type 2 diabetes risk-associated variants. Nat Genet. 2014;46:136-143.
48. Sandhu KS, Shi C, SjölinderM, et al. Nonallelic transvection of multiple imprinted loci isorganized by the H19 imprinting control regionduring germline development. Genes Dev. 2009;23:2598-2603.
49. Zhao Z, Tavoosidana G, Sjölinder M, et al. Circular chromosome conformation capture (4C) uncovers extensive networks of epige-netically regulated intra-and interchromosomal interactions. Nat Genet. 2006;38:1341-1347.
50. Dekker J, Rippe K, Dekker M, Kleckner N. Capturing chromosome conformation. Science. 2002;295:1306-1311.
51. Dostie J, Richmond TA, Arnaout RA, et al. Chromosome Conformation Capture Carbon Copy (5C):amassively parallel solution for mapping interactions between genomic elements. Genome Res. 2006;16:1299-1309.
52. Zhang J, Poh HM, Peh SQ, et al. Ch IA-PET analysis of transcrip-tional chromatin interactions. Methods. 2012;58:289-299.